AU723649B2 - Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts - Google Patents

Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts Download PDF

Info

Publication number
AU723649B2
AU723649B2 AU13459/97A AU1345997A AU723649B2 AU 723649 B2 AU723649 B2 AU 723649B2 AU 13459/97 A AU13459/97 A AU 13459/97A AU 1345997 A AU1345997 A AU 1345997A AU 723649 B2 AU723649 B2 AU 723649B2
Authority
AU
Australia
Prior art keywords
tobacco
age
ages
smoke
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU13459/97A
Other languages
English (en)
Other versions
AU1345997A (en
Inventor
Richard J Bucala
Anthony Cerami
Clara J. Cerami
Henry W. Founds
Helen Vlassara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picower Institute for Medical Research
Synvista Therapeutics Inc
Original Assignee
Alteon Inc
Picower Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteon Inc, Picower Institute for Medical Research filed Critical Alteon Inc
Publication of AU1345997A publication Critical patent/AU1345997A/en
Application granted granted Critical
Publication of AU723649B2 publication Critical patent/AU723649B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A24B15/365—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having nitrogen and sulfur as hetero atoms in the same ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D3/00—Tobacco smoke filters, e.g. filter-tips, filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces for cigars or cigarettes
    • A24D3/06—Use of materials for tobacco smoke filters
    • A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Botany (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
AU13459/97A 1995-12-26 1996-12-23 Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts Ceased AU723649B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US921995P 1995-12-26 1995-12-26
US921895P 1995-12-26 1995-12-26
US60/009219 1995-12-26
US60/009218 1995-12-26
PCT/US1996/020526 WO1997023783A1 (fr) 1995-12-26 1996-12-23 Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU42527/00A Division AU4252700A (en) 1995-12-26 2000-06-20 Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts

Publications (2)

Publication Number Publication Date
AU1345997A AU1345997A (en) 1997-07-17
AU723649B2 true AU723649B2 (en) 2000-08-31

Family

ID=26679210

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13459/97A Ceased AU723649B2 (en) 1995-12-26 1996-12-23 Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts

Country Status (7)

Country Link
EP (1) EP0877943A1 (fr)
JP (1) JP2000507346A (fr)
CN (1) CN1211321A (fr)
AU (1) AU723649B2 (fr)
CA (1) CA2241924A1 (fr)
IN (1) IN191280B (fr)
WO (1) WO1997023783A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5921248A (en) * 1997-03-28 1999-07-13 The Picower Institute For Medical Research Tobacco combination product filter
EP1175155A4 (fr) * 1999-04-15 2005-10-19 Fox Chase Cancer Ct Procede destine a reduire la predisposition a la formation de tumeurs provoquees par la 3-desoxyglucosone et les precurseurs de cette substance
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
SE0400683D0 (sv) * 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
CN106353434B (zh) * 2016-10-21 2018-10-09 中国烟草总公司郑州烟草研究院 一种定量测定烟草中Amadori化合物的分析方法
CN106769349B (zh) * 2017-01-06 2020-01-21 上海君联医疗设备有限公司 血液中异常糖基化蛋白细胞的检测方法
CN107202843B (zh) * 2017-06-07 2019-08-30 贵州省烟草科学研究院 LC-MS/MS法同时测定烟草中游离氨基酸和Amadori化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4827949A (en) * 1987-09-16 1989-05-09 Sunas Ernest C Method of treating tobacco and tobacco produced thereby
CA1332572C (fr) * 1988-01-29 1994-10-18 Anthony Cerami Methode et agents de prevention de la formation de taches sur les dents
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
MX9705449A (es) * 1995-01-18 1998-02-28 Alteon Inc Uso de compuestos de tiazolio para evitar y revertir la formacion de productos finales de glicosilacion avanzada.

Also Published As

Publication number Publication date
IN191280B (fr) 2003-10-25
JP2000507346A (ja) 2000-06-13
EP0877943A1 (fr) 1998-11-18
WO1997023783A1 (fr) 1997-07-03
AU1345997A (en) 1997-07-17
CA2241924A1 (fr) 1997-07-03
CN1211321A (zh) 1999-03-17

Similar Documents

Publication Publication Date Title
Bachi et al. Measurement of urinary 8-epi-prostaglandin F2α, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and nonsmokers
Schleicher et al. Increased accumulation of the glycoxidation product N (epsilon)-(carboxymethyl) lysine in human tissues in diabetes and aging.
US5850840A (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Morrow et al. The isoprostanes: current knowledge and directions for future research
Rijcken et al. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1.
Sutton et al. Relationship between cigarette yields, puffing patterns, and smoke intake: evidence for tar compensation?
JP4067562B2 (ja) 進行性グリコシル化最終生成物の生成を阻止し、反転するためのチアゾリウム化合物の使用
Crawford et al. Biomarkers of environmental tobacco smoke in preschool children and their mothers
US6110968A (en) Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Scott et al. Effects of cigarette smoking on solid and liquid intragastric distribution and gastric emptying
Willers et al. Passive smoking and childhood asthma: urinary cotinine levels in children with asthma and in referents
Eugenín et al. Prenatal to early postnatal nicotine exposure impairs central chemoreception and modifies breathing pattern in mouse neonates: a probable link to sudden infant death syndrome
Malaveille et al. Levels of mutagens in the urine of smokers of black and blond tobacco correlate with their risk of bladder cancer
Podzolkov et al. Relation between tobacco smoking/electronic smoking and albuminuria/vascular stiffness in young people without cardiovascular diseases
AU723649B2 (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Llaquet et al. Biological matrices for the evaluation of exposure to environmental tobacco smoke during prenatal life and childhood
Bogden et al. Composition of tobaccos from countries with high and low incidences of lung cancer. I. Selenium, polonium-210, Alternaria, tar, and nicotine
Rosenthal et al. Time-course of cigarette smoke contamination of clinical hydrogen breath-analysis tests.
WO1997023783A9 (fr) Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion
Clark et al. Passive smoking amongst asthmatic children. Questionnaire or objective assessment?
Kraal et al. The response of polymorphonuclear leukocytes to chemotictic stimulation for smokers and non‐smokers
US5688653A (en) 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US5854000A (en) Methods for measurement predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
AU4252700A (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Behera et al. Serum surfactant protein-A levels in chronic bronchitis and its relation to smoking

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired